Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 29 entries
Sorted by: Best Match Show Resources per page
Serum levels of vascular endothelial growth factor in non-alcoholic fatty liver disease.

Annals of gastroenterology

Papageorgiou MV, Hadziyannis E, Tiniakos D, Georgiou A, Margariti A, Kostas A, Papatheodoridis GV.
PMID: 28243042
Ann Gastroenterol. 2017;30(2):209-216. doi: 10.20524/aog.2016.0107. Epub 2016 Dec 01.

BACKGROUND: This study aimed to assess the significance of serum levels of vascular endothelial growth factor (VEGF) in non-alcoholic fatty liver disease (NAFLD).METHODS: Sixty-seven consecutive NAFLD patients and 47 healthy controls who visited our liver clinics between May 2008...

Cite
Papageorgiou MV, Hadziyannis E, Tiniakos D, et al. Serum levels of vascular endothelial growth factor in non-alcoholic fatty liver disease. Ann Gastroenterol. 2016;30(2):209-216doi: 10.20524/aog.2016.0107.
Papageorgiou, M. V., Hadziyannis, E., Tiniakos, D., Georgiou, A., Margariti, A., Kostas, A., & Papatheodoridis, G. V. (2017). Serum levels of vascular endothelial growth factor in non-alcoholic fatty liver disease. Annals of gastroenterology, 30(2), 209-216. https://doi.org/10.20524/aog.2016.0107
Papageorgiou, Maria-Vasiliki, et al. "Serum levels of vascular endothelial growth factor in non-alcoholic fatty liver disease." Annals of gastroenterology vol. 30,2 (2017): 209-216. doi: https://doi.org/10.20524/aog.2016.0107
Papageorgiou MV, Hadziyannis E, Tiniakos D, Georgiou A, Margariti A, Kostas A, Papatheodoridis GV. Serum levels of vascular endothelial growth factor in non-alcoholic fatty liver disease. Ann Gastroenterol. 2017;30(2):209-216. doi: 10.20524/aog.2016.0107. Epub 2016 Dec 01. PMID: 28243042; PMCID: PMC5320034.
Copy Download .nbib Format: NLM
Significance of the .

Annals of gastroenterology

Konstantinou D, Margariti E, Hadziyannis E, Pectasides D, Papatheodoridis GV.
PMID: 24714782
Ann Gastroenterol. 2014;27(1):53-59.

BACKGROUND: The 13C-caffeine breath test (CBT) is a non-invasive, quantitative test of liver function which has been shown to correlate inversely to the Child-Pugh score. The aim of the study was to determine the utility of CBT in the...

Cite
Konstantinou D, Margariti E, Hadziyannis E, et al. Significance of the . Ann Gastroenterol. 2014;27(1):53-59
Konstantinou, D., Margariti, E., Hadziyannis, E., Pectasides, D., & Papatheodoridis, G. V. (2014). Significance of the . Annals of gastroenterology, 27(1), 53-59.
Konstantinou, Dimitrios, et al. "Significance of the ." Annals of gastroenterology vol. 27,1 (2014): 53-59.
Konstantinou D, Margariti E, Hadziyannis E, Pectasides D, Papatheodoridis GV. Significance of the . Ann Gastroenterol. 2014;27(1):53-59. PMID: 24714782; PMCID: PMC3959537.
Copy Download .nbib Format: NLM
Spontaneous bacterial peritonitis (SBP): clinical, laboratory, and prognostic features. A single-center experience.

European journal of internal medicine

Thanopoulou AC, Koskinas JS, Hadziyannis SJ.
PMID: 12020628
Eur J Intern Med. 2002 May;13(3):194-198. doi: 10.1016/s0953-6205(02)00027-4.

BACKGROUND: The aim of the present study was to assess the clinical and laboratory characteristics, the course, and the factors influencing the hospital mortality and relapse rate of spontaneous bacterial peritonitis (SBP) in cirrhotic patients admitted in a single...

Cite
Thanopoulou AC, Koskinas JS, Hadziyannis SJ. Spontaneous bacterial peritonitis (SBP): clinical, laboratory, and prognostic features. A single-center experience. Eur J Intern Med. 2002;13(3):194-198doi: 10.1016/s0953-6205(02)00027-4.
Thanopoulou, A. C., Koskinas, J. S., & Hadziyannis, S. J. (2002). Spontaneous bacterial peritonitis (SBP): clinical, laboratory, and prognostic features. A single-center experience. European journal of internal medicine, 13(3), 194-198. https://doi.org/10.1016/s0953-6205(02)00027-4
Thanopoulou, Anastasia C., et al. "Spontaneous bacterial peritonitis (SBP): clinical, laboratory, and prognostic features. A single-center experience." European journal of internal medicine vol. 13,3 (2002): 194-198. doi: https://doi.org/10.1016/s0953-6205(02)00027-4
Thanopoulou AC, Koskinas JS, Hadziyannis SJ. Spontaneous bacterial peritonitis (SBP): clinical, laboratory, and prognostic features. A single-center experience. Eur J Intern Med. 2002 May;13(3):194-198. doi: 10.1016/s0953-6205(02)00027-4. PMID: 12020628.
Copy Download .nbib Format: NLM
Acute chest syndrome in sickle-cell trait; Two case reports in persons of Mediterranean origin and review of the literature.

European journal of internal medicine

Dourakis SP, Alexopoulou A, Papageorgiou C, Kaloterakis A, Hadziyannis SJ.
PMID: 15288680
Eur J Intern Med. 2004 Jul;15(4):248-250. doi: 10.1016/j.ejim.2004.03.010.

Sickle-cell trait has been characterized as a benign condition. However, life-threatening complications sometimes develop. Acute chest syndrome (ACS) is usually described in homozygous sickle cell disease, but it rarely develops in individuals with sickle-cell trait. Two cases of ACS...

Cite
Dourakis SP, Alexopoulou A, Papageorgiou C, et al. Acute chest syndrome in sickle-cell trait; Two case reports in persons of Mediterranean origin and review of the literature. Eur J Intern Med. 2004;15(4):248-250doi: 10.1016/j.ejim.2004.03.010.
Dourakis, S. P., Alexopoulou, A., Papageorgiou, C., Kaloterakis, A., & Hadziyannis, S. J. (2004). Acute chest syndrome in sickle-cell trait; Two case reports in persons of Mediterranean origin and review of the literature. European journal of internal medicine, 15(4), 248-250. https://doi.org/10.1016/j.ejim.2004.03.010
Dourakis, Spyros P., et al. "Acute chest syndrome in sickle-cell trait; Two case reports in persons of Mediterranean origin and review of the literature." European journal of internal medicine vol. 15,4 (2004): 248-250. doi: https://doi.org/10.1016/j.ejim.2004.03.010
Dourakis SP, Alexopoulou A, Papageorgiou C, Kaloterakis A, Hadziyannis SJ. Acute chest syndrome in sickle-cell trait; Two case reports in persons of Mediterranean origin and review of the literature. Eur J Intern Med. 2004 Jul;15(4):248-250. doi: 10.1016/j.ejim.2004.03.010. PMID: 15288680.
Copy Download .nbib Format: NLM
Correction: DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B.

Antiviral therapy

Papatheodoridis GV, Rigopoulou EI, Papatheodoridi M, Zachou K, Xourafas V, Gatselis N, Hadziyannis E, Vlachogiannakos J, Manolakopoulos S, Dalekos GN.
PMID: 30091421
Antivir Ther. 2018;23(8):711. doi: 10.3851/IMP3261.

No abstract available.

Cite
Papatheodoridis GV, Rigopoulou EI, Papatheodoridi M, et al. Correction: DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B. Antivir Ther. 2018;23(8):711doi: 10.3851/IMP3261.
Papatheodoridis, G. V., Rigopoulou, E. I., Papatheodoridi, M., Zachou, K., Xourafas, V., Gatselis, N., Hadziyannis, E., Vlachogiannakos, J., Manolakopoulos, S., & Dalekos, G. N. (2018). Correction: DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B. Antiviral therapy, 23(8), 711. https://doi.org/10.3851/IMP3261
Papatheodoridis, George V, et al. "Correction: DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B." Antiviral therapy vol. 23,8 (2018): 711. doi: https://doi.org/10.3851/IMP3261
Papatheodoridis GV, Rigopoulou EI, Papatheodoridi M, Zachou K, Xourafas V, Gatselis N, Hadziyannis E, Vlachogiannakos J, Manolakopoulos S, Dalekos GN. Correction: DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B. Antivir Ther. 2018;23(8):711. doi: 10.3851/IMP3261. PMID: 30091421.
Copy Download .nbib Format: NLM
Bacterial DNA is a prognostic factor for mortality in patients who recover from spontaneous bacterial peritonitis.

Annals of gastroenterology

Mani I, Vrioni G, Hadziyannis E, Alexopoulos T, Vasilieva L, Tsiriga A, Tsiamis C, Tsakris A, Dourakis SP, Alexopoulou A.
PMID: 34815652
Ann Gastroenterol. 2021 Nov-Dec;34(6):852-861. doi: 10.20524/aog.2021.0665. Epub 2021 Sep 14.

BACKGROUND: Spontaneous bacterial peritonitis (SBP) is associated with a high mortality. The aim was to investigate whether bacterial deoxyribonucleic acid (bactDNA) could offer an accurate identification of pathogens and to explore its prognostic role during and early after an...

Cite
Mani I, Vrioni G, Hadziyannis E, et al. Bacterial DNA is a prognostic factor for mortality in patients who recover from spontaneous bacterial peritonitis. Ann Gastroenterol. 2021;34(6):852-861doi: 10.20524/aog.2021.0665.
Mani, I., Vrioni, G., Hadziyannis, E., Alexopoulos, T., Vasilieva, L., Tsiriga, A., Tsiamis, C., Tsakris, A., Dourakis, S. P., & Alexopoulou, A. (2021). Bacterial DNA is a prognostic factor for mortality in patients who recover from spontaneous bacterial peritonitis. Annals of gastroenterology, 34(6), 852-861. https://doi.org/10.20524/aog.2021.0665
Mani, Iliana, et al. "Bacterial DNA is a prognostic factor for mortality in patients who recover from spontaneous bacterial peritonitis." Annals of gastroenterology vol. 34,6 (2021): 852-861. doi: https://doi.org/10.20524/aog.2021.0665
Mani I, Vrioni G, Hadziyannis E, Alexopoulos T, Vasilieva L, Tsiriga A, Tsiamis C, Tsakris A, Dourakis SP, Alexopoulou A. Bacterial DNA is a prognostic factor for mortality in patients who recover from spontaneous bacterial peritonitis. Ann Gastroenterol. 2021 Nov-Dec;34(6):852-861. doi: 10.20524/aog.2021.0665. Epub 2021 Sep 14. PMID: 34815652; PMCID: PMC8596224.
Copy Download .nbib Format: NLM
Association of TIM-3 with BCLC Stage, Serum PD-L1 Detection, and Response to Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma.

Cancers

Tampaki M, Ionas E, Hadziyannis E, Deutsch M, Malagari K, Koskinas J.
PMID: 31952209
Cancers (Basel). 2020 Jan 15;12(1). doi: 10.3390/cancers12010212.

Considering the increasing importance of immune checkpoints in tumor immunity we investigated the clinical relevance of serum T-cell immunoglobulin and mucin domain-3 (TIM-3) in patients with hepatocellular carcinoma (HCC). Serum TIM-3 levels were measured and their association with HCC...

Cite
Tampaki M, Ionas E, Hadziyannis E, et al. Association of TIM-3 with BCLC Stage, Serum PD-L1 Detection, and Response to Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma. Cancers (Basel). 2020;12(1)doi: 10.3390/cancers12010212.
Tampaki, M., Ionas, E., Hadziyannis, E., Deutsch, M., Malagari, K., & Koskinas, J. (2020). Association of TIM-3 with BCLC Stage, Serum PD-L1 Detection, and Response to Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma. Cancers, 12(1), . https://doi.org/10.3390/cancers12010212
Tampaki, Maria, et al. "Association of TIM-3 with BCLC Stage, Serum PD-L1 Detection, and Response to Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma." Cancers vol. 12,1 (2020). doi: https://doi.org/10.3390/cancers12010212
Tampaki M, Ionas E, Hadziyannis E, Deutsch M, Malagari K, Koskinas J. Association of TIM-3 with BCLC Stage, Serum PD-L1 Detection, and Response to Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma. Cancers (Basel). 2020 Jan 15;12(1). doi: 10.3390/cancers12010212. PMID: 31952209; PMCID: PMC7016746.
Copy Download .nbib Format: NLM
Abnormalities in Cu and Zn levels in acute hepatitis of different etiologies.

Hippokratia

Papanikolopoulos K, Alexopoulou A, Dona A, Hadziyanni E, Vasilieva L, Dourakis S.
PMID: 25336878
Hippokratia. 2014 Apr;18(2):144-9.

BACKGROUND: Copper (Cu) and Zinc (Zn) are essential trace elements which play an important role in various biological processes. Zn deficiency is common in liver diseases while Cu deficiency is rarely reported. To determine whether serum Cu and Zn...

Cite
Papanikolopoulos K, Alexopoulou A, Dona A, et al. Abnormalities in Cu and Zn levels in acute hepatitis of different etiologies. Hippokratia. 2014;18(2):144-9
Papanikolopoulos, K., Alexopoulou, A., Dona, A., Hadziyanni, E., Vasilieva, L., & Dourakis, S. (2014). Abnormalities in Cu and Zn levels in acute hepatitis of different etiologies. Hippokratia, 18(2), 144-9.
Papanikolopoulos, K, et al. "Abnormalities in Cu and Zn levels in acute hepatitis of different etiologies." Hippokratia vol. 18,2 (2014): 144-9.
Papanikolopoulos K, Alexopoulou A, Dona A, Hadziyanni E, Vasilieva L, Dourakis S. Abnormalities in Cu and Zn levels in acute hepatitis of different etiologies. Hippokratia. 2014 Apr;18(2):144-9. PMID: 25336878; PMCID: PMC4201401.
Copy Download .nbib Format: NLM
Research as a part of education.

Scandinavian journal of gastroenterology. Supplement

de Dombal FT, Hirschowitz BI, Okuda K, Hadziyannis SJ, el-Zayadi A.
PMID: 2814351
Scand J Gastroenterol Suppl. 1989;161:10-1; discussion 11-3. doi: 10.3109/00365528909091052.

No abstract available.

Cite
de Dombal FT, Hirschowitz BI, Okuda K, et al. Research as a part of education. Scand J Gastroenterol Suppl. 1989;161:10-1; discussion 11-3doi: 10.3109/00365528909091052.
de Dombal, F. T., Hirschowitz, B. I., Okuda, K., Hadziyannis, S. J., & el-Zayadi, A. (1989). Research as a part of education. Scandinavian journal of gastroenterology. Supplement, 16110-1; discussion 11-3. https://doi.org/10.3109/00365528909091052
de Dombal, F T, et al. "Research as a part of education." Scandinavian journal of gastroenterology. Supplement vol. 161 (1989): 10-1; discussion 11-3. doi: https://doi.org/10.3109/00365528909091052
de Dombal FT, Hirschowitz BI, Okuda K, Hadziyannis SJ, el-Zayadi A. Research as a part of education. Scand J Gastroenterol Suppl. 1989;161:10-1; discussion 11-3. doi: 10.3109/00365528909091052. PMID: 2814351.
Copy Download .nbib Format: NLM
Conversion and Reversion Rates of Tuberculosis Screening Assays in Patients With Rheumatic Diseases and Negative Baseline Screening Under Long-Term Biologic Treatment.

Pathogens & immunity

Thomas K, Hadziyannis E, Hatzara C, Makris A, Tsalapaki C, Lazarini A, Klavdianou K, Antonatou K, Koutsianas C, Vassilopoulos D.
PMID: 32258853
Pathog Immun. 2020 Feb 26;5(1):34-51. doi: 10.20411/pai.v5i1.349. eCollection 2020.

BACKGROUND: To determine the conversion and reversion rates of tuberculosis (TB) screening tests (Tuberculin Skin Test-TST, Interferon Gamma Release Assay-IGRA: T-SPOT.TB) during biologic treatment in patients with rheumatic diseases and negative baseline screening.METHODS: This was a long-term, longitudinal cohort...

Cite
Thomas K, Hadziyannis E, Hatzara C, et al. Conversion and Reversion Rates of Tuberculosis Screening Assays in Patients With Rheumatic Diseases and Negative Baseline Screening Under Long-Term Biologic Treatment. Pathog Immun. 2020;5(1):34-51doi: 10.20411/pai.v5i1.349.
Thomas, K., Hadziyannis, E., Hatzara, C., Makris, A., Tsalapaki, C., Lazarini, A., Klavdianou, K., Antonatou, K., Koutsianas, C., & Vassilopoulos, D. (2020). Conversion and Reversion Rates of Tuberculosis Screening Assays in Patients With Rheumatic Diseases and Negative Baseline Screening Under Long-Term Biologic Treatment. Pathogens & immunity, 5(1), 34-51. https://doi.org/10.20411/pai.v5i1.349
Thomas, Konstantinos, et al. "Conversion and Reversion Rates of Tuberculosis Screening Assays in Patients With Rheumatic Diseases and Negative Baseline Screening Under Long-Term Biologic Treatment." Pathogens & immunity vol. 5,1 (2020): 34-51. doi: https://doi.org/10.20411/pai.v5i1.349
Thomas K, Hadziyannis E, Hatzara C, Makris A, Tsalapaki C, Lazarini A, Klavdianou K, Antonatou K, Koutsianas C, Vassilopoulos D. Conversion and Reversion Rates of Tuberculosis Screening Assays in Patients With Rheumatic Diseases and Negative Baseline Screening Under Long-Term Biologic Treatment. Pathog Immun. 2020 Feb 26;5(1):34-51. doi: 10.20411/pai.v5i1.349. eCollection 2020. PMID: 32258853; PMCID: PMC7104555.
Copy Download .nbib Format: NLM
Is HCV core antigen a reliable marker of viral load? An evaluation of HCV core antigen automated immunoassay.

Annals of gastroenterology

Hadziyannis E, Minopetrou M, Georgiou A, Spanou F, Koskinas J.
PMID: 24714621
Ann Gastroenterol. 2013;26(2):146-149.

BACKGROUND: Hepatitis C viral (HCV) load detection and quantification is routinely accomplished by HCV RNA measurement, an expensive but essential test, both for the diagnosis and treatment of chronic hepatitis C (CHC). HCV core antigen (Ag) testing has been...

Cite
Hadziyannis E, Minopetrou M, Georgiou A, et al. Is HCV core antigen a reliable marker of viral load? An evaluation of HCV core antigen automated immunoassay. Ann Gastroenterol. 2013;26(2):146-149
Hadziyannis, E., Minopetrou, M., Georgiou, A., Spanou, F., & Koskinas, J. (2013). Is HCV core antigen a reliable marker of viral load? An evaluation of HCV core antigen automated immunoassay. Annals of gastroenterology, 26(2), 146-149.
Hadziyannis, Emilia, et al. "Is HCV core antigen a reliable marker of viral load? An evaluation of HCV core antigen automated immunoassay." Annals of gastroenterology vol. 26,2 (2013): 146-149.
Hadziyannis E, Minopetrou M, Georgiou A, Spanou F, Koskinas J. Is HCV core antigen a reliable marker of viral load? An evaluation of HCV core antigen automated immunoassay. Ann Gastroenterol. 2013;26(2):146-149. PMID: 24714621; PMCID: PMC3959936.
Copy Download .nbib Format: NLM
Circulating and liver tissue levels of retinol-binding protein-4 in non-alcoholic fatty liver disease.

Hepatology research : the official journal of the Japan Society of Hepatology

Schina M, Koskinas J, Tiniakos D, Hadziyannis E, Savvas S, Karamanos B, Manesis E, Archimandritis A.
PMID: 19624771
Hepatol Res. 2009 Oct;39(10):972-8. doi: 10.1111/j.1872-034X.2009.00534.x. Epub 2009 Jul 13.

AIM: Retinol-binding protein-4 (RBP4) has been proposed as a new adipokine that regulates insulin action in muscles and the liver, and contributes to the pathogenesis of insulin resistance. As non-alcoholic fatty liver disease (NAFLD) is related to insulin resistance,...

Cite
Schina M, Koskinas J, Tiniakos D, et al. Circulating and liver tissue levels of retinol-binding protein-4 in non-alcoholic fatty liver disease. Hepatol Res. 2009;39(10):972-8doi: 10.1111/j.1872-034X.2009.00534.x.
Schina, M., Koskinas, J., Tiniakos, D., Hadziyannis, E., Savvas, S., Karamanos, B., Manesis, E., & Archimandritis, A. (2009). Circulating and liver tissue levels of retinol-binding protein-4 in non-alcoholic fatty liver disease. Hepatology research : the official journal of the Japan Society of Hepatology, 39(10), 972-8. https://doi.org/10.1111/j.1872-034X.2009.00534.x
Schina, Maria, et al. "Circulating and liver tissue levels of retinol-binding protein-4 in non-alcoholic fatty liver disease." Hepatology research : the official journal of the Japan Society of Hepatology vol. 39,10 (2009): 972-8. doi: https://doi.org/10.1111/j.1872-034X.2009.00534.x
Schina M, Koskinas J, Tiniakos D, Hadziyannis E, Savvas S, Karamanos B, Manesis E, Archimandritis A. Circulating and liver tissue levels of retinol-binding protein-4 in non-alcoholic fatty liver disease. Hepatol Res. 2009 Oct;39(10):972-8. doi: 10.1111/j.1872-034X.2009.00534.x. Epub 2009 Jul 13. PMID: 19624771.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 29 entries